Pharnext Financial Statements From 2010 to 2024

ALPHA Stock  EUR 0.0002  0.00  0.00%   
Pharnext financial statements provide useful quarterly and yearly information to potential Pharnext SA investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Pharnext financial statements helps investors assess Pharnext's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Pharnext's valuation are summarized below:
Pharnext SA does not presently have any trending fundamental ratios for analysis.
Check Pharnext financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharnext's main balance sheet or income statement drivers, such as , as well as many indicators such as . Pharnext financial statements analysis is a perfect complement when working with Pharnext Valuation or Volatility modules.
  
This module can also supplement various Pharnext Technical models . Check out the analysis of Pharnext Correlation against competitors.

Pharnext SA Company Shares Outstanding Analysis

Pharnext's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Shares Outstanding

 = 

Public Shares

-

Repurchased

More About Shares Outstanding | All Equity Analysis

Current Pharnext Shares Outstanding

    
  875.25 M  
Most of Pharnext's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharnext SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition

Based on the latest financial disclosure, Pharnext SA has 875.25 M of shares currently outstending. This is 384.81% higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The shares outstanding for all France stocks is 53.06% lower than that of the firm.

Pharnext SA Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Pharnext's current stock value. Our valuation model uses many indicators to compare Pharnext value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pharnext competition to find correlations between indicators driving Pharnext's intrinsic value. More Info.
Pharnext SA is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pharnext's earnings, one of the primary drivers of an investment's value.

About Pharnext Financial Statements

Pharnext shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Pharnext investors may analyze each financial statement separately, they are all interrelated. The changes in Pharnext's assets and liabilities, for example, are also reflected in the revenues and expenses on on Pharnext's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Pharnext SA, a clinical-stage biopharmaceutical company, develops therapeutics for severe orphan and common neurodegenerative diseases in France. The company was founded in 2007 and is based in Issy-Les-Moulineaux, France. Pharnext S is traded on Paris Stock Exchange in France.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pharnext Stock Analysis

When running Pharnext's price analysis, check to measure Pharnext's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharnext is operating at the current time. Most of Pharnext's value examination focuses on studying past and present price action to predict the probability of Pharnext's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharnext's price. Additionally, you may evaluate how the addition of Pharnext to your portfolios can decrease your overall portfolio volatility.